Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 101 - 150 out of 18,761

Document Document Title
WO/2015/125138A1
The present invention relates to the alleviation of adverse side effects resulting from statin therapy. The present invention further relates to the use of an inhibitor of leukotriene C 4 (LTC4) mediated activity for alleviating at least...  
WO/2015/122067A1
Provided are: a citrus seed extract-containing composition with which a novel function of citrus (particularly, a citrus seed extract) can be sufficiently exhibited; a food; a drug; and a method for producing the citrus seed extract-cont...  
WO/2015/119126A1
The purpose of the present invention is to provide a novel compound having a selective JAK3-inhibiting effect and excellent oral absorption. Moreover, the purpose of the present invention is to provide a medical drug useful, on the basis...  
WO/2015/118019A1
The present invention refers to novel substituted thiazole and oxazole compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties. The compounds are useful in the treatment or prophylaxis of diseases associated with P2X...  
WO/2015/119249A1
Provided are a novel myogenesis accelerator, amyotrophy suppressor, medicinal composition, and TAZ activator. The myogenesis accelerator, amyotrophy suppressor, medicinal composition, and TAZ activator according to the present invention ...  
WO/2015/118365A1
The present invention is directed to compositions and methods for the prevention, inhibition, and/or treatment of progressive fibrosis present in various fibroproliferative disorders. In particular, embodiments of the present invention r...  
WO/2015/118019A9
The present invention refers to novel substituted thiazole and oxazole compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties. The compounds are useful in the treatment or prophylaxis of diseases associated with P2X...  
WO/2015/117010A3
Compositions are directed to BCL2-associated athanogene 3 (BAG3) molecules and agents which modulate expression of BAG3 molecules. Pharmaceutical composition for administration to patients, for example, patients with heart failure, compr...  
WO/2015/111602A1
Provided are: a method for producing adult oligodendrocyte-type-2 astrocyte progenitor cells from proliferative oligodendrocyte-type-2 astrocyte progenitor cells; and a pharmaceutical composition having as an effectivecomponent thereof a...  
WO/2015/109935A1
The invention generally relates to compounds of formula (I) with neural protective effect, and preparation and uses thereof. The compounds have multiple mechanisms or functions, for example, inhibition of monoamine oxidase and cholineste...  
WO/2015/109666A1
Disclosed are an ester group-containing aromatic propionamide compound, and a preparation method therefor and uses thereof, and provides a chemical structure formula of the new ester group-containing aromatic propionamide compound. The c...  
WO/2015/106268A1
The present disclosure relates to methods, uses, pharmaceutical compositions and kits comprising a sGC stimulator or a pharmaceutically acceptable salt thereof, alone or in combination with one or more additional therapeutic agents, for ...  
WO/2015/106290A1
The present disclosure provides antibodies and antigen-binding fragments capable of penetrating cells via an ENT transporter, such as humanized antibodies. The disclosure also provides conjugates comprising the antibodies or antigen-bind...  
WO/2015/099175A1
The purpose of the present invention is to provide an antibody exhibiting antagonistic action against IL-33, in particular, an isolated human anti-IL-33 neutralizing monoclonal antibody or fragment thereof in which the amino acid sequenc...  
WO/2015/098963A1
Provided is a method for promoting the expression of calreticulin in at least one type of eukaryotic cell. Also provided is a synthetic peptide that can be used in said method. The method provided by the present invention includes prepar...  
WO/2015/093634A1
The present invention relates to a pharmaceutical composition containing an extract of Cichorium intybus as an active ingredient for preventing or treating myoatrophy; a food composition containing an extract of Cichorium intybus for pre...  
WO/2015/090232A1
The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also pro...  
WO/2015/089575A1
The present invention relates generally to a method of diagnosing and/or monitoring the development or progress of chronic fatigue syndrome. More particularly, the present invention relates to a method of diagnosing and/or monitoring the...  
WO/2015/095713A1
The invention provides enantiopure deuterium-enriched bupropion, pharmaceutical compositions, and methods of treating neurological disorders, movement disorders, cardiovascular disorders, metabolic disorders, and other disorders using en...  
WO/2015/094772A1
Methods of increasing skeletal muscle protein synthesis in a subject are provided. Methods of increasing or maintaining mammalian target of rapamycin (mTOR) activation are also provided. Such methods include a step of administering at le...  
WO/2015/093901A1
The present invention relates to a composition containing TM-53 and TM-54 as an active ingredient for inducing or promoting myocyte differentiation, a pharmaceutical composition for muscle regeneration, and a pharmaceutical composition f...  
WO/2015/089452A1
The invention relates to the use of an animal-protein-free botulinum toxin composition to treat a disease, disorder or condition in a patient in need thereof whereby the animal-protein-free botulinum toxin composition exhibits a longer l...  
WO/2015/085118A1
The present invention is directed to a method of treating spasticity in a human subject, comprising administering intrathecally to the subject a therapeutically effective amount of dantrolene or a pharmaceutically acceptable salt thereof...  
WO/2015/082938A1
The present invention relates to a compound of formula I, or a pharmaceutically acceptable salt thereof : (I) wherein: n is 0 or 1; R1 is selected from H, alkyl and aralkyl, wherein said alkyl and aralkyl groups may be optionally substit...  
WO/2015/078935A1
The application relates to means, which derive from TAL effectors and TALENs. The structure of the means of the application is especially adapted for partial or full deletion of at least one DNA tandem repeat, more particularly for parti...  
WO/2015/077353A1
Methods of suppressing cachexia in a mammal with cancer comprising administering HDAC inhibitors are provided. Aspects include methods of administering an HDAC class 1 and 2b inhibitor in an amount effective to substantially maintain the...  
WO/2015/073813A3
Provided herein are interfering molecules and pharmaceutical combinations comprising such interfering molecules that modulate the Hippo signaling pathway. Also provided are methods of treating and preventing a disease or condition associ...  
WO/2015/069669A1
Nanostructure conjugates, methods for their preparation, and methods for their use are described. The nanostructure conjugates are useful in inhibiting, activating, and modulating extrasynaptic receptors and ion channels, and in treating...  
WO/2015/070158A1
The present invention provides methods comprising the in vivo delivery of small nucleic acid molecules capable of mediating RNA interference and reducing the expression of myostatin, wherein the small nucleic acid molecules are introduce...  
WO/2015/069115A1
The invention related to methods of treatment of an individual suffering from or at risk of suffering from a selective estrogen-receptor modulator (SERM) induced adverse drug reaction. The invention additionally relates to a pharmaceutic...  
WO/2015/064585A1
The purpose of the present invention is to provide a pharmaceutical composition or method which is widely applicable to myopathies accompanying a decrease in muscle strength and can increase muscle strength or delay the progression of a ...  
WO/2015/061779A1
Methods for treating a subject in need thereof are provided which include administering a pharmaceutical composition comprising a protein transduction reagent-modified reprogramming protein to the subject, wherein the protein transductio...  
WO/2015/060430A1
The purpose of the present invention is to provide a method for screening substances that participate in metabolic conversion and a kit for screening substances that participate in metabolic conversion. Said problem can be solved with mu...  
WO/2015/060650A2
The present invention relates to a composition for preventing or treating amyotrophic lateral sclerosis, the composition containing, as an active ingredient, two or more isoforms of a hepatocyte growth factor (HGF) or a polynucleotide en...  
WO/2015/060650A3
The present invention relates to a composition for preventing or treating amyotrophic lateral sclerosis, the composition containing, as an active ingredient, two or more isoforms of a hepatocyte growth factor (HGF) or a polynucleotide en...  
WO/2015/056713A1
The problem of the present invention is to provide a peptide that functions as a c-Met agonist. The present invention provides a peptide complex formed from two or more peptides that couple with a c-Met protein and a linker that joins th...  
WO/2015/058161A1
Studies of the pathogenic mechanisms underlying human myopathies and muscular dystrophies often require animal models, but models of some human diseases are not yet available. The present invention provides methods to promote the engraft...  
WO/2015/051234A3
Methods and compositions for treating lupus nephritis and muscle atrophy with anti-TWEAK antibodies are provided. Methods that include administering therapeutically effective amounts of anti-TWEAK antibodies to human subjects already rec...  
WO/2015/050160A1
The present invention provides an anti-aging pharmaceutical composition for muscle containing as the active ingredient parathyroid hormone, a parathyroid hormone derivative, or a salt thereof. Preferably the parathyroid hormone derivativ...  
WO/2015/051283A1
Methods for modulating expression of SMN1 and/or SMN2 in cells obtained from subjects having ALS or in subjects having ALS using single stranded oligonucleotides are provided. Methods for treating ALS using single stranded oligonucleotid...  
WO/2015/049630A1
This relates to the use of an IGF-1 mimetic in human therapy. In particular, disclosed herein is the use of an IGF-1 precursor protein, particularly a human IGF-1 precursor protein, comprising the E-peptide for the treatment of Spinal an...  
WO/2015/042685A1
Compounds which inhibit the formation and/or accumulation of RNA foci, such as those due to polynucleotide repeats (e.g., trinucleotide repeats) are described herein. Also described herein are uses of such compounds, such as for the inhi...  
WO/2015/037656A1
 Autophagy-regulating miRNA molecules according to the present invention are formed from base sequences represented by any of SEQ ID NO: 1-203 in the sequence listing. These miRNA molecules were identified using an miRNA screening meth...  
WO/2015/037659A1
 An aqueous solution formulation containing compound (I) can be manufactured by performing the following steps: a first step in which a solution is prepared by dissolving, in an organic solvent, a compound represented by formula (I) or...  
WO/2015/037001A1
The present invention providesamethod for inducing glucose uptake in a muscle cell by inhibiting Trim32 protein in the cell and to a method for inducing glucose uptake in a muscle cell, by increasing the abundance of plakoglobin protein ...  
WO/2015/035460A1
An antisense oligonucleotide of 10 to 50 nucleotides comprising a targeting sequence complementary to a region near or within intron 6, intron 7, or exon 8 of the Survival Motor Neuron 2 (SMN2) gene pre-mRNA.  
WO/2015/037720A1
 Provided is a muscle repair promoter intended for use in a target of which rapid absorption of protein is required, and containing as an effective ingredient a lactoprotein mixture that includes casein protein and whey protein, wherei...  
WO/2015/032812A1
The invention relates to a composition for controlling or preventing locomotor disorders, especially locomotor disorders that may affect mammals including humans or pets or recreational animals, especially cats, dogs and horses. The comp...  
WO/2015/035171A1
The present invention provides methods for treating muscle atrophy by administering a PPARδ agonist.  
WO/2015/022927A1
The purpose of the present invention is to provide a novel AMP-activated protein kinase (AMPK) activator with a high safety. An AMPK activator that comprises a liver hydrolysate as an active ingredient.  

Matches 101 - 150 out of 18,761